New Research on Post-Colectomy Ulcerative Colitis Patients’ Quality of Life, Treatment Satisfaction

New Research on Post-Colectomy Ulcerative Colitis Patients’ Quality of Life, Treatment Satisfaction
The conclusions of a new survey regarding quality of life for Ulcerative Colitis patients were recently released online and through social media channels as a means of improving care and treatment of the disease. The survey, which was commissioned and funded by MSD, the UK subsidiary of Merck & Co., Inc., together with Crohn’s and Colitis UK (CCUK), studied 684 people with Ulcerative Colitis (UC) who answered questions regarding the level of disease control, the impact on quality of life, treatment satisfaction, and satisfaction after having a colectomy, a surgical procedure where the colon is removed, partially or completely. The majority of the surveyed patients were women (74%), and the ages varied between less than 24 years old (18%), 25–39 (46%) and 40–54 years of age (29%). Between the participants, nearly 1 in 10 had undergone a colectomy. These patients reported frequent fatigue (74%), abdominal pain (54%) and diarrhea (33%). While fatigue was reported as the worst symptom to cope with, the most common post-operative complications were related to infections (43%), followed by pouch leakage (31%) and pouchitis (23%), a condition characterized by inflammation of the ileal pouch (an artificial rectum surgically created out of ileal gut tissue in patients who have had a colectomy). The results of the survey were announced in parallel with the ongoing NICE Multiple Technology Appraisal (MTA) of biologics to treat moderate to severe UC. While current NICE guidelines restrict biologics use in hospitalized severe UC, the survey's finding suggest the need for a reevaluation of the guidelines to treat moderate-to-severe UC that fails conventional therapies. Chris Probert, Professor of Gastroenterology at the University of Liverpool, Honorary Consulta
Subscribe or to access all post and page content.


  1. Sharon Morley says:

    Help please.
    We have a son who’s just turned 14 – Will was diagnosed with severe ulcerative pan-colitis 2 years ago. After going through all of the usual drugs he is now on Infliximab which has mainly worked in reducing the inflammation in his colon. He will be on Infliximab indefinitely however our enormous difficulty is that Will suffers with underlying fatigue which does not go away and when combined with severe stomach pain, headaches, a c-diff infection he has hardly attended school in the past 2 years. We tried a ‘drug holiday’ a year ago but the fatigue did not lift and his colon returned to a raging mess – back to Infliximab.
    Will doesn’t have quality of life and his specialist has no idea what to do. Is there any one who knows of others suffering the same as our son? Surely Will is not the only person like this?! We desperately need help to get him back into participating in life again.
    We live in Adelaide, South Australia. Regards

  2. Justin says:

    Have you considered in Indigo Naturalis? Conventional UC treatments such as Imuran, Enemas and Mesalazine stopped working for me. I really wanted to avoid infliximab due to the side effects. My doctor sent me to a doctor of combined medicine in Hiroshima ( I live in Japan). I was skeptical of alternative medicine but I decided to give it a go. 6 months later I have stopped all conventional medicine and I take 2 sachets of Indigo Naturalis daily. My bowel movements are back to normal, I have no fatigue and no dietary restrictions. The side effects from immunotherapy have all gone. Indigo Naturalis gave me my life back.

    You can buy the herb in Australia quite easily; however, I recommend contacting Hiroshima Sky clinic. They use a special mixture and also monitor my health very closely. They also have many patients in foreign countries and can speak English. Either way I recommend trying Indigo Naturalis. But don’t just take my word for it look at scholarly articles on Qing Dai (Indigo Naturalis) for UC.


Leave a Comment

Your email address will not be published. Required fields are marked *